Recent Finacing
Recent Raise
ImmPACT Bio is a clinical-stage cell therapy company developing logic-gate and engineered CAR T-cell therapies—including a CD19/CD20 bispecific candidate (IMPT-514) in Phase 1b/2 for autoimmune and cancer indications.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at ImmPACT Bio.
